Who are Verapamil Hydrochloride's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cleviprex, Sular, Norvasc, Plendil, Dynacirc, Cardene.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/verapamil-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Verapamil Hydrochloride — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Verapamil Hydrochloride (Verapamil Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

marketed Calcium channel blocker L-type calcium channels (slow channels) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Verapamil Hydrochloride (Verapamil Hydrochloride) — Pfizer Inc.. Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Verapamil Hydrochloride TARGET	Verapamil Hydrochloride	Pfizer Inc.	marketed	Calcium channel blocker	L-type calcium channels (slow channels)
Cleviprex	CLEVIDIPINE	Chiesi	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	2008-01-01
Sular	NISOLDIPINE	Azurity	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1995-01-01
Norvasc	amlodipine	Pfizer Inc.	marketed	Calcium channel blocker (dihydropyridine)	Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6	1992-07-31
Plendil	FELODIPINE	AstraZeneca	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent T-type calcium channel subunit alpha-1H	1991-01-01
Dynacirc	ISRADIPINE	Smithkline Beecham	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1D	1990-01-01
Cardene	NICARDIPINE	Hikma Intl Pharms	marketed	Dihydropyridine Calcium Channel Blocker	Voltage-dependent T-type calcium channel subunit alpha-1H	1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Ain Shams University · 1 drug in this class
Bioprojet · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Handok Inc. · 1 drug in this class
Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
Hospital de Clinicas de Porto Alegre · 1 drug in this class
Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Verapamil Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/verapamil-hydrochloride. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab